A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases

Br J Cancer. 1992 Jun;65(6):913-5. doi: 10.1038/bjc.1992.191.

Abstract

A phase I study was undertaken in order to establish the maximum tolerated dose of intra-hepatic arterial 5-fluorouracil (5-FU) when given in combination with systemic folinic acid. Patients with colorectal liver metastases (n = 10) received escalating doses of 5-FU as a 24 h infusion with a fixed dose (400 mg m-2) of intravenous folinic acid once per week. Dose limiting toxicity (WHO grade greater than 2) was encountered at 2 g m-2 5-FU. Principal adverse effects were diarrhoea, vomiting and oral ulceration. The recommended dose for phase II studies is 1.5 g m-2 week-1 24 h 5-FU regional infusion with 400 mg m-2 week-1 intravenous folinic acid.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Colorectal Neoplasms / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Female
  • Fluorouracil / administration & dosage*
  • Fluorouracil / adverse effects
  • Humans
  • Leucovorin / administration & dosage*
  • Leucovorin / adverse effects
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary*
  • Male
  • Middle Aged

Substances

  • Leucovorin
  • Fluorouracil